Figure 1.

Ad5ASM improves glucose tolerance in mice. A, B) Wild-type (A) or diabetic db/db mice (B) were infected with Ad5GFP or Ad5ASM (5×10⁸ PFU/mouse), then deprived of food for 18 h, and IPGTT was performed by administering a glucose load of 2 mg/g body weight 3 d after the infection. Values of area under the blood glucose curve were calculated (right panels). C) Primary cultured rat hepatocytes were treated with ASM (1 U/ml) for 2 h (left panel) or infected with Ad5GFP or Ad5ASM (10 PFU/cell; right panel), followed by measurement of 2-deoxy-d-[1-³H]glucose uptake after a 1-h incubation period. D) Hepatic glycogen content in wild-type mice was determined under food-deprivation conditions at 3 d after the adenoviral infection. E) Glycogen content was determined in rat hepatocytes at 8 h after ASM treatment (left panel) or normal (200 mg/dl) and high-dose glucose (600 mg/dl) (right panel) treatment with Ad5GFP or Ad5ASM infection. Data are means ± sd from ≥4 independent experiments. *P < 0.05.